Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
